Extractables and Leachables in Biologics

The terms extractables and leachables refer to the chemical substances that can migrate from container closure systems into a drug product. Extractables are substances released from a container or closure system under aggressive conditions, whereas leachables refer to those substances that migrate into the drug product under normal storage conditions. Understanding these two components is critical to ensuring safety and efficacy, particularly for biologics susceptible to degradation and performance issues.

This section offers clarity on the definitions and implications of E and L for biologic products:

• Extractables: Identify compounds that might leach into the product under exaggerated conditions, such as elevated temperatures or extended contact times. Common extractables include plasticizers, stabilizers, and residual monomers.
• Leachables: These are compounds that may begin to enter the drug product during its shelf life. They can originate from the packaging materials once conditions, such as temperature or pH, facilitate the migration process.

Both extractables and leachables can pose significant risks to patient safety, including adverse effects of unknown or toxic compounds. Therefore, thorough investigation and risk assessment are paramount during the packaging selection process and throughout the life cycle of the biologic.

Regulatory Guidance on E and L Studies

Regulatory bodies around the world have outlined specific recommendations concerning E and L testing for biologics. These guidelines ensure that safety and quality standards concerning packaging materials are met. Understanding these regulations forms the foundational step for compliance and can aid in the decision-making process regarding container closure systems.

Key regulatory documents include:

• FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics
• EMA Guideline on the Quality of the Chemical Contaminants in Medicinal Products
• ICH Q3D: Guideline for Elemental Impurities

These documents underscore the need for robust E and L study processes during product development, emphasizing a risk management approach that incorporates toxicological assessments and packaging selection criteria. Each document provides insights into expectations for testing methodologies, permissible limits, and study design considerations.

Step 1: Conducting a Risk Assessment for E and L

The first proactive step in managing extractables and leachables in cold chain and frozen storage biologics is conducting a thorough risk assessment. A risk assessment provides a structured analysis of potential hazards associated with packaging materials. Here’s how to undertake this assessment:

1. Identify all materials: Create a comprehensive inventory of all materials used in the container and closure systems, including rubber stoppers, plastic syringes, and vials.
2. Evaluate intended use: Define the specific application, working conditions (temperature, duration), and potential interactions of the biologic with the materials used.
3. Consider historical data: Consult existing extractables and leachables data from similar products, focusing on their composition, migratory behavior, and toxicological impact.
4. Utilize analytical methods: Employ established analytical techniques like Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS) to identify potential E and L.

Each of these steps will provide insights critical to evaluating leachables risk and aid decision-making within packaging development.

Step 2: Designing E and L Studies

After identifying potential risks, the next step is designing E and L studies that adhere to regulatory expectations while fulfilling the requirements specific to the biologic product. This includes:

• Defining study objectives: Establish clear objectives for the E and L studies, focusing on identifying extractables under exaggerated conditions and leachables under simulated storage conditions.
• Choosing appropriate methodologies: Select analytical methods based on target molecules and their concentrations. Gas chromatography for volatiles and liquid chromatography for larger biomolecules may be useful.
• Establishing contact conditions: Simulate real-world storage conditions to assess leachables; consider factors like temperature, duration, and real-time versus accelerated aging studies.
• Reviewing outcomes: Establish thresholds for action based on toxicological assessments for each of the identified E and L compounds.

Effective study design is critical to fulfilling both regulatory requirements and ensuring the safety and efficacy of the biologic product. Collaboration with toxicology and CMC teams during this process is essential.

Step 3: Performing Toxicological Assessments

Toxicological assessment is a crucial step in managing E and L and is often guided by regulatory documents and best practices. The objective of this assessment is to evaluate the risk posed by identified leachables to human health. The following outlines the necessary steps:

• Characterization of leachables: Identify and characterize all leachables that were detected in the product. This includes analyzing their chemical structure and potential health impacts.
• Risk analysis: Utilize a systematic approach to analyze potential exposure levels to leachables based on the concentration in the drug product and the anticipated dosage received by patients.
• Toxicological profiles: Compile data on toxicological profiles from reputable sources, focusing on known adverse effects, carcinogenicity, mutagenicity, and reproductive toxicity for all leachables.
• Conduct safety assessments: Evaluate the potential risks using scales such as the Margin of Exposure (MoE) for low-level contaminants compared to established safety thresholds.

By integrating toxicological assessments into the E and L process, CMC leads and teams can comprehensively evaluate the safety of packaging materials and their potential impact on patient safety.

Step 4: Selecting Appropriate Packaging and Container Closure Systems

After concluding E and L studies and toxicological assessments, the next critical step involves selecting appropriate packaging solutions. The choice of packaging can significantly impact the stability and efficacy of biologic products. The following guidelines can assist teams in making informed decisions:

• Material compatibility: Ensure the compatibility of the selected materials with the biologic product, considering aspects like pH, storage temperature, and time.
• Previous performance: Leverage available data from previous evaluations of the materials to predict their behavior as part of the container closure system.
• Regulatory compliance: Confirm that packaging providers comply with relevant regulatory standards and have demonstrated satisfactory E and L testing records.
• Flexibility and scalability: Assess whether the selected packaging can be scaled for commercial production while maintaining compliance and integrity of the biologic.

The packaging selection process should be dynamic, involving ongoing evaluations as new data comes to light, and taking product development and changes in regulations into account.

Step 5: Long-term Monitoring and Reassessment

Post-launch, it is vital to implement long-term monitoring of E and L for biologics throughout their product lifecycle. Continuous assessment ensures that any new data regarding extractables or leachables can be addressed promptly. Here’s how to establish a robust monitoring framework:

• Periodic testing: Schedule regular testing of E and L as part of ongoing quality assurance, particularly if there are changes to the manufacturing process or supply chain.
• Review supplier performance: Establish supplier audits to ensure that the packaging materials continue to meet regulatory standards and internal safety benchmarks.
• Data integration: Update risk assessments and toxicological evaluations with findings from monitoring initiatives, ensuring all relevant stakeholders are aware of changes.
• Regulatory updates: Stay informed about updates to regulatory guidelines and adapt processes as necessary to maintain compliance.

This ongoing process helps to ensure that any potential risks are addressed proactively and that the biologic remains safe for patient use throughout its shelf life.

Conclusion

Comprehensive management of extractables and leachables is essential in the development and commercialization of biologic products, especially those requiring cold chain and frozen storage. Adopting a structured approach, from initial risk assessments through to long-term monitoring, allows CMC leads, packaging development teams, and toxicology professionals to mitigate risks effectively while remaining compliant with global regulatory requirements. By following the best practices outlined in this guide, organizations can enhance product safety and maintain compliance across markets in the US, EU, and UK.